A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

NCT05503797

Status	RECRUITING
Phase	Phase 2
Sponsor	Fore Biotherapeutics
Enrollment	254 participants

Key Eligibility Criteria

Inclusion (39)

- Subprotocol A:
- Male and female, e10 years of age, and weighing e30 kg.
- Histologic diagnosis of a solid tumor or primary CNS tumor.
- Documentation of BRAF gene fusion in tumor and/or blood detected by an analytically validated test by DNA sequencing or RNA (transcriptome) sequencing.
- Have an archival tissue sample available meeting protocol requirements.

... and 34 more (see full listing online)

Exclusion (34)

- Subprotocol A:
- Prior treatment with RAF/BRAF inhibitors active for Class 2 BRAF alterations for advanced unresectable or metastatic disease.
- Prior treatment with a MEK inhibitor.
- Malignancy with co-occurring activating RAS mutation(s) at any time.
- Uncontrolled intercurrent illness that would limit compliance with study requirements.

... and 29 more (see full listing online)

Locations (67 total)

Precision NextGen Oncology & Research Center, Beverly Hills, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
University of California Los Angeles Rheumatology, Westwood, Los Angeles, California, United States
... and 64 more locations